Marker Therapeutics, Inc.MRKRNASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
58.62%
↑ 413% above average
Average (39q)
-18.71%
Historical baseline
Range
High:225.15%
Low:-832.19%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 58.62% |
| Q2 2025 | 27.50% |
| Q1 2025 | 4.76% |
| Q4 2024 | -61.54% |
| Q3 2024 | -4.00% |
| Q2 2024 | 7.41% |
| Q1 2024 | 12.90% |
| Q4 2023 | 8.82% |
| Q3 2023 | -217.24% |
| Q2 2023 | 150.88% |
| Q1 2023 | -18.75% |
| Q4 2022 | 42.17% |
| Q3 2022 | 25.23% |
| Q2 2022 | 6.72% |
| Q1 2022 | 0.00% |
| Q4 2021 | 20.67% |
| Q3 2021 | -15.38% |
| Q2 2021 | 18.75% |
| Q1 2021 | 8.57% |
| Q4 2020 | -9.37% |
| Q3 2020 | -14.29% |
| Q2 2020 | 0.71% |
| Q1 2020 | -27.03% |
| Q4 2019 | 7.50% |
| Q3 2019 | 1.64% |
| Q2 2019 | -4.27% |
| Q1 2019 | 96.08% |
| Q4 2018 | -832.19% |
| Q3 2018 | 21.95% |
| Q2 2018 | -36.67% |
| Q1 2018 | -18.11% |
| Q4 2017 | 34.87% |
| Q3 2017 | -76.47% |
| Q2 2017 | 23.00% |
| Q1 2017 | -53.48% |
| Q4 2016 | 35.52% |
| Q3 2016 | -128.71% |
| Q2 2016 | 225.15% |
| Q1 2016 | 74.15% |
| Q4 2015 | -144.35% |